Cookies show us what works. Privacy
Cookies show us what works. Privacy
ImmunityBio (IBRX) has not announced its next earnings date. The next report covers the quarter ending Sep 30, 2026. A year earlier it reported the same quarter on Nov 4, 2025. Analysts expect earnings per share of -$0.05 (3 analysts) on revenue of $59M.
Last report, Aug 4, 2026: EPS -$0.08 against -$0.09 expected (+11.1%). Beat the EPS estimate in 6 of the last 8 reports.
| Reported | Quarter ended | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Aug 4, 2026 | Jun 30, 2026 | -$0.08 | -$0.09 | +11.1% |
| May 7, 2026 | Mar 31, 2026 | -$0.08 | -$0.07 | -14.3% |
| Feb 23, 2026 | Dec 31, 2025 | -$0.06 | -$0.11 | +45.8% |
| Nov 4, 2025 | Sep 30, 2025 | -$0.07 | -$0.10 | +30.0% |
| Aug 5, 2025 | Jun 30, 2025 | -$0.10 | -$0.10 | 0.0% |
| May 12, 2025 | Mar 31, 2025 | -$0.15 | -$0.16 | +6.3% |
| Mar 3, 2025 | Dec 31, 2024 | -$0.08 | -$0.13 | +38.5% |
| Nov 12, 2024 | Sep 30, 2024 | -$0.12 | -$0.18 | +33.3% |
ImmunityBio (IBRX) has not announced its next earnings date. The next report covers the quarter ending Sep 30, 2026. A year earlier it reported the same quarter on Nov 4, 2025.
-$0.05 a share, the average of 3 analysts, for the quarter ending Sep 30, 2026. The revenue estimate is $59M.
Yes. Last report, Aug 4, 2026: EPS -$0.08 against -$0.09 expected (+11.1%).
Report dates come from the Alpha Vantage earnings calendar and stay expected until the company confirms them. EPS is as reported against the analyst average; the next-day move is close to close. Not investment advice.